
The computational biologist behind Aqtual has spent two decades learning how to pull useful signals from noisy biology. Now she is building a company around a deceptively simple idea: the blood carries a running record of what the body is doing.

From a protein-engineering bench to the CEO seat at Vivace Therapeutics, Craig Gibbs has built a career around one stubborn question: how does promising biology become a drug program that can actually move?